Compare · ACHV vs LMDX
ACHV vs LMDX
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and LumiraDx Limited (LMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and LMDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LMDX is the larger of the two at $2.23B, about 4.0x ACHV ($562.6M).
- ACHV has hit the wire 10 times in the past 4 weeks while LMDX has been quiet.
- ACHV has more recent analyst coverage (8 ratings vs 4 for LMDX).
- Company
- Achieve Life Sciences Inc.
- LumiraDx Limited
- Price
- $5.49+7.13%
- $0.02-53.80%
- Market cap
- $562.6M
- $2.23B
- 1M return
- +14.39%
- -
- 1Y return
- +46.27%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 10
- 0
- Recent ratings
- 8
- 4
ACHV
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV
- SEC Form DEF 14A filed by Achieve Life Sciences Inc.
- SEC Form 4 filed by Director Waldman Reid Alexander
- SEC Form 4 filed by Director Farrow Jeffrey S
- New insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)
- New insider Farrow Jeffrey S claimed no ownership of stock in the company (SEC Form 3)
- Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update
- Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
- SEC Form PRE 14A filed by Achieve Life Sciences Inc.
- SEC Form EFFECT filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points